Silo Pharma Inc. (NASDAQ:SILO) saw its shares decline 22% on Friday after the company revealed plans for a private placement, priced at-the-market under Nasdaq rules, that could total up to $11.7 million.
Under definitive agreements, the firm will issue and sell 619,965 shares of common stock. Alongside those shares, the company will grant Series A-3 and Series A-4 warrants, each allowing for the purchase of up to 619,965 shares. The stated purchase price for the common shares and associated warrants is $6.452 per share.
The transaction is expected to generate approximately $4 million in gross proceeds initially, before deducting placement agent fees and other offering expenses. If the warrants are fully exercised on a cash basis, Silo Pharma could receive up to about $7.7 million in additional cash; however, the company explicitly noted there is no assurance any warrants will be exercised.
The warrants will carry an exercise price of $6.21 per share and will be exercisable immediately upon issuance. The longer-dated Series A-3 warrants will expire five years after the effective date of the Resale Registration Statement. The shorter-dated Series A-4 warrants are set to expire eighteen months after that same effective date.
H.C. Wainwright & Co. is serving as the exclusive placement agent for the transaction. The offering is anticipated to close on or about July 10, 2026, subject to customary closing conditions.
Silo Pharma said it plans to allocate net proceeds from the offering to working capital and general corporate purposes. The company is a development-stage biopharmaceutical firm focused on creating therapeutics for stress-induced psychiatric disorders, chronic pain, and central nervous system diseases.
Market reaction and context
The near-term market reaction was a sharp decline in Silo Pharma's share price, reflecting investor concern about dilution from the share issuance and associated warrants. The structure of the financing - an at-the-market placement under Nasdaq rules with immediately exercisable warrants - is central to that investor response.
What remains uncertain
- Whether holders of the warrants will exercise them, which would provide additional cash to the company but also increase share count.
- Completion of the offering on or about July 10, 2026, which is dependent on customary closing conditions.